Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J Moran

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
European Urology Focus|July 30, 2017
Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOTStephen A Mihalcik, Ming-Hui Chen, Michelle H Braccioforte, et al.
Brachytherapy|August 21, 2019
Long-term biochemical outcomes using cesium-131 in prostate brachytherapyBrian J Moran, Stephanie R Rice, Arpit M Chhabra, et al.
Brachytherapy|February 26, 2011
Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practiceJona A Hattangadi, Ming-Hui Chen, Michelle H Braccioforte, et al.
Brachytherapy|August 26, 2018
Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancerManuj Agarwal, Arpit M Chhabra, Neha Amin, et al.
JAMA Oncology|July 17, 2015
Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate CancerAnn C Raldow, Danjie Zhang, Ming-Hui Chen, et al.
Brachytherapy|September 13, 2015
Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapyAnn C Raldow, Danjie Zhang, Ming-Hui Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2016
Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy AloneMai Anh Huynh, Ming-Hui Chen, Jing Wu, et al.
Urologic Oncology|July 28, 2021
The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapyDavid D Yang, Ming-Hui Chen, Jing Wu, et al.
Cancer|May 1, 2015
Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk diseaseFlorence K Keane, Ming-Hui Chen, Danjie Zhang, et al.
European Urology|September 22, 2015
Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of DeathMai Anh Huynh, Ming-Hui Chen, Jing Wu, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
European Urology Focus|July 30, 2017
Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOTStephen A Mihalcik, Ming-Hui Chen, Michelle H Braccioforte, et al.
Brachytherapy|August 21, 2019
Long-term biochemical outcomes using cesium-131 in prostate brachytherapyBrian J Moran, Stephanie R Rice, Arpit M Chhabra, et al.
Brachytherapy|February 26, 2011
Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practiceJona A Hattangadi, Ming-Hui Chen, Michelle H Braccioforte, et al.
Brachytherapy|August 26, 2018
Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancerManuj Agarwal, Arpit M Chhabra, Neha Amin, et al.
JAMA Oncology|July 17, 2015
Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate CancerAnn C Raldow, Danjie Zhang, Ming-Hui Chen, et al.
Brachytherapy|September 13, 2015
Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapyAnn C Raldow, Danjie Zhang, Ming-Hui Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2016
Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy AloneMai Anh Huynh, Ming-Hui Chen, Jing Wu, et al.
Urologic Oncology|July 28, 2021
The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapyDavid D Yang, Ming-Hui Chen, Jing Wu, et al.
Cancer|May 1, 2015
Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk diseaseFlorence K Keane, Ming-Hui Chen, Danjie Zhang, et al.
European Urology|September 22, 2015
Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of DeathMai Anh Huynh, Ming-Hui Chen, Jing Wu, et al.
Pageof 6